Additionally, Neo-CheckRay (NCT03875573) is an active phase II trial examining neoadjuvant chemotherapy and radiotherapy with the addition of durvalumab or oleclumab (anti-CD73 antibody) in luminal B breast cancer. This evidence concerns the gene NT5E and breast cancer.